HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reaffirmed a Buy rating on Ocugen (NASDAQ:OCGN) and increased the price target from $5 to $7.
January 24, 2024 | 11:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst has maintained a Buy rating on Ocugen and raised the price target from $5 to $7, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a bullish perspective on the stock, suggesting that the analyst sees potential for the stock to grow beyond its current price. This can often lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100